Article
Expanded approval for daratumumab in multiple myeloma
- Author:
- Edited by Jame Abraham
- MD
- FACP; report prepared by Jane de Lartigue
- PhD
Article
Ribociclib: another CDK inhibitor hits the mark in breast cancer
- Author:
- Edited by Jame Abraham
- MD
- FACP; report prepared by Jane de Lartigue
- PhD
Article
Approval makes olaratumab the first first-line treatment option for soft tissue sarcoma in more than 40 years
- Author:
- Edited by Jame Abraham
- MD
- FACP; report prepared by Jane de Lartigue
- PhD
Article
Rucaparib – second PARP inhibitor hits the market for ovarian cancer
- Author:
- Edited by Jame Abraham
- MD
- FACP; report prepared by Jane de Lartigue
- PhD
Article
Lenvatinib expands its reach into renal cell carcinoma
- Author:
- Edited by Jame Abraham
- MD; report prepared by Jane de Lartigue
- PhD
The US Food and Drug Administration (FDA) expanded the approval of the multitargeted tyrosine kinase inhibitor lenvatinib to a second indication...
Article
Pembrolizumab is the first immune checkpoint inhibitor to receive approval for head and neck cancer
- Author:
- Edited by Jame Abraham
- MD
- FACP; report prepared by Jane de Lartigue
- PhD
Article
Fourth approved indication for ofatumumab in chronic lymphocytic leukemia
- Author:
- Edited by Jame Abraham
- MD
- FACP; report prepared by Jane de Lartigue
- PhD
Article
Renal cell carcinoma approval adds another notch to cabozantinib’s belt
- Author:
- Edited by Jame Abraham
- MD
- FACP; report prepared by Jane de Lartigue
- PhD
Article
Alectinib provides a new option for ALK-positive NSCLC patients after progression on crizotinib
- Author:
- Edited by Jame Abraham
- MD
- FACP; report prepared by Jane de Lartigue
- PhD
Article
Panobinostat: a novel mechanism of action shows promise in multiple myeloma
- Author:
- Edited by Jame Abraham
- MD
- FACP; report prepared by Jane de Lartigue
- PhD
Article
Palonosetron and netupitant for prevention of chemotherapy-induced nausea and vomiting
- Author:
- Edited by Jame Abraham
- MD
- PhD; report prepared by Jane de Lartigue
- PhD
Article
Omacetaxine for chronic or accelerated phase CML in patients with resistance or intolerance to TKIs
- Author:
- Edited by Jame Abraham
- MD